+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are comparing the effects of two treatment combinations in adults with stage IV or recurrent non-squamous non-small cell lung cancer NSCLC that has a PD-L1 expression of 1% or higher. This phase 3 trial investigates whether Nivolumab and Relatlimab combined with chemotherapy works differently than Pembrolizumab with chemotherapy as first-line treatment for this condition. The study is sponsored by Bristol-Myers Squibb and uses a randomized parallel design. Participants will be assigned to one of two groups one group receives Nivolumab and Relatlimab with chemotherapy drugs, while the other group receives Pembrolizumab with chemotherapy. Chemotherapy may include drugs such as Carboplatin, Pemetrexed, or Cisplatin, given at specified doses on specific days. Treatment schedules and doses are carefully planned, and participants are treated during the trial period. During the study, participants undergo regular assessments to measure overall survival, progression-free survival, response rates, and duration of response, with follow-up lasting up to five years. Researchers also track adverse events and immune-related side effects for up to 2.5 years. Quality of life is monitored through symptom questionnaires. Assessments include imaging scans and laboratory tests to evaluate disease status and treatment effects. The total duration of participation may extend over several years to capture long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
329 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.

Age: 18Years +All GendersPhase 2Phase 3
770 locations
O

Actively Recruiting

Researchers are gathering real-world clinical and patient-reported data from cancer patients with breast, lung, ovarian, multiple myeloma, or acute myelogenous leukemia who are actively receiving treatment. This observational study aims to add to Carevives registry using an electronic care planning system that includes remote symptom monitoring, focusing on patients treatment experiences. Participants complete a baseline survey either in person with a secure device or remotely using their own electronic device. Then, they are asked to complete weekly electronic patient-reported outcome surveys via the Carevive platform for at least 12 weeks, with the option to continue these weekly surveys as long as they remain on treatment. During the study, participants provide regular symptom updates through online surveys using their phones, tablets, or computers. Researchers collect this information to create a comprehensive data set over one year. The study tracks participant responses remotely, aiming to capture ongoing treatment experiences and symptom changes without requiring in-person visits beyond the initial baseline survey.

Age: 18Years +All Genders
7 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of an adjuvant treatment combining sacituzumab tirumotecan with pembrolizumab compared to treatment chosen by physicians in people with triple-negative breast cancer TNBC who received neoadjuvant therapy but did not achieve a complete response at surgery. This Phase 3, randomized, open-label study aims to determine if the combination improves invasive disease-free survival compared to pembrolizumab alone or pembrolizumab combined with capecitabine. Participants are randomly assigned to one of two groups. One group receives pembrolizumab every 6 weeks along with sacituzumab tirumotecan every 2 weeks for a total of 24 weeks, with premedication including antihistamines, H2 antagonists, acetaminophen, and dexamethasone before sacituzumab tirumotecan infusions. The other group receives pembrolizumab every 6 weeks alone or combined with capecitabine taken orally twice daily on specific days over 24 weeks. The study treatments are given intravenously or by mouth according to schedule. During the study, participants undergo regular assessments to monitor disease status, quality of life, and adverse events. Researchers measure invasive disease-free survival for up to approximately 77 months, along with overall survival and distant recurrence-free survival for up to about 101 months. Quality of life is evaluated using standardized questionnaires at baseline and periodically for up to 60 months. Safety is closely monitored, including recording adverse events and treatment discontinuations. The total study duration may last over a decade, with long-term follow-up to assess outcomes and treatment effects.

Age: 18Years +All GendersPhase 3
314 locations
P

Actively Recruiting

Researchers are evaluating the new medicine PF-08634404 in combination with chemotherapy compared to the current standard treatment pembrolizumab with chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer NSCLC. The study includes adults with Stage IIIBIIIC or Stage IV squamous or non-squamous NSCLC who are not candidates for surgery or curative chemoradiotherapy and have not received prior treatment for advanced disease. Participants are assigned to two parts based on tumor type squamous NSCLC Part 1 or non-squamous NSCLC Part 2. Each participant is randomly assigned to receive either PF-08634404 or pembrolizumab with chemotherapy followed by maintenance therapy. Treatment is given through intravenous infusions in cycles, continuing as long as it is effective and safe. Different chemotherapy regimens are used depending on the tumor type. Throughout the study, participants attend regular visits for treatment and health monitoring. Cancer response is assessed every 6 weeks for the first 48 weeks and then every 12 weeks. Researchers will measure overall survival, progression-free survival, objective response rates, duration of response, adverse events, laboratory results, drug levels, immune response, and quality of life using questionnaires. The study lasts up to approximately 39 months with ongoing safety and effectiveness evaluations.

Age: 18Years +All GendersPhase 3
484 locations